Sagimet Biosciences Inc.
NASDAQ: SGMT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David Happel
- Employees
- 16
- Headquarters
- San Mateo, United States
- IPO year
- 2023
- Market cap
- $225.8M
- Website
- https://www.sagimet.com
Loading SGMT…
Loading profile data…Frequently asked questions about SGMT
What does Sagimet Biosciences Inc. (SGMT) do?
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective...
Where does SGMT trade?
Sagimet Biosciences Inc. (SGMT) trades on the NASDAQ.
What sector is SGMT in?
Sagimet Biosciences Inc. (SGMT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Sagimet Biosciences Inc.?
David Happel is the chief executive officer of Sagimet Biosciences Inc. (SGMT).
Where is Sagimet Biosciences Inc. headquartered?
Sagimet Biosciences Inc. is headquartered in United States.
Does SGMT pay a dividend?
Sagimet Biosciences Inc. (SGMT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SGMT go public?
Sagimet Biosciences Inc. (SGMT) completed its initial public offering in 2023.